NOT KNOWN DETAILS ABOUT HEMGENIX

Quantity of qualified sufferers: CDEC reviewed the uncertainty in the volume of people with moderately serious to extreme hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific experts consulted by CADTH indicated that some individuals who are classified as getting mild or average sickness can have a extreme bleeding phenotype, w